Comparative Pharmacology
Head-to-head clinical analysis: ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE versus LABETALOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE versus LABETALOL HYDROCHLORIDE.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs LABETALOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.
Labetalol is a non-selective beta-adrenoceptor blocker and selective alpha-1 adrenoceptor blocker. It reduces myocardial contractility, heart rate, and peripheral vascular resistance.
Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 mL/kg) per appointment, not to exceed 500 mg (12.5 mL). 1:200,000 epinephrine formulation may be used; maximum dose same.
Oral: Initial 100 mg twice daily, titrate up to 200-400 mg twice daily; maximum 2400 mg/day. IV: 20 mg slow IV over 2 minutes, then 40-80 mg every 10 minutes as needed up to 300 mg total; or continuous IV infusion at 0.5-2 mg/min.
None Documented
None Documented
Articaine: terminal half-life ~20 minutes (0.33 h) in plasma; clinical context: rapid elimination limits systemic toxicity. Epinephrine: short half-life ~2 minutes; clinical effect terminated by uptake and metabolism.
Terminal elimination half-life: 6-8 hours. In renal impairment, half-life may be slightly prolonged but not clinically significant; in hepatic impairment, half-life may be significantly prolonged.
Articaine is primarily metabolized by plasma esterases; its inactive metabolite articainic acid is excreted renally (approximately 90% as metabolites, <2% unchanged). Epinephrine is metabolized by COMT and MAO; metabolites and small amounts unchanged are excreted in urine (~90% renal).
Primarily hepatic metabolism; ~5% excreted unchanged in urine; ~55-60% as glucuronide conjugates in urine; fecal excretion <5%.
Category A/B
Category A/B
Alpha/Beta Agonist
Alpha/Beta-Blocker